

PTO/5B/08b (04-09)  
Approved for use through 05/31/2009. CMB 0051-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
Sheet	1	of	1	Application Number	10/526,829-Conf. #5802
				Filing Date	September 26, 2005
				First Named Inventor	Marie-Isabel Aguilar
				Art Unit	1644
				Examiner Name	Marianne Dibrino
				Attorney Docket Number	31471/44171

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BOWNDS et al., Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. <i>J. Immunol.</i> 24: 1-9 (2001)	
		CHEN et al., Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. <i>J. Immunol.</i> 165: 948-955 (2000).	
		GNJATIC et al., CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. <i>Proc. Natl. Acad. Sci. USA.</i> 99: 11813-11818 (2002).	
		JAGER et al., Simulation humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. <i>J. Exp. Med.</i> 187: 265-70 (1998).	
		STEER et al., $\beta$ -amino acids: Versatile peptidomimetics. <i>Curr. Med. Chem.</i> 9: 811-822 (2002).	
		WEBB et al., Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. <i>J. Biol. Chem.</i> 279: 23438-23446 (2004).	

Examiner Signature	/Marianne Dibrino/	Date Considered	07/09/2010
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.